How to buy Syndax Pharmaceuticals stock (SNDX)

Syndax Pharmaceuticals is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.93 – a decrease of 1.19% over the previous week. Syndax Pharmaceuticals employs 184 staff and has a trailing 12-month revenue of around $16 million.

Our top picks for where to buy Syndax Pharmaceuticals stock

Buy Syndax Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Syndax Pharmaceuticals stock price (NASDAQ: SNDX)

Use our graph to track the performance of SNDX stocks over time.

Syndax Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$12.93
52-week range	$12.73 - $25.34
50-day moving average more info button	$17.10
200-day moving average more info button	$19.91
Wall St. target price	$36.62
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.64

Is it a good time to buy Syndax Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Syndax Pharmaceuticals price performance over time

Historical closes compared with the close of $13.07 from 2024-12-24

1 week (2024-12-19)	1.71%
1 month (2024-11-27)	-20.84%
3 months (2024-09-26)	-28.03%
6 months (2024-06-26)	-34.26%

1 year (2023-12-26)	-38.72%
2 years (2022-12-23)	-46.21%
3 years (2021-12-23)	22.47
5 years (2019-12-26)	44.42%

Syndax Pharmaceuticals financials

Revenue TTM	$16 million
Gross profit TTM	$139.7 million
Return on assets TTM	-48.67%
Return on equity TTM	-81.88%
Profit margin	0%
Book value	$4.28
Market Capitalization more info button	$1.1 billion

TTM: trailing 12 months

Syndax Pharmaceuticals share dividends

We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.

Syndax Pharmaceuticals share price volatility

Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $12.73 up to $25.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 0.917. This would suggest that Syndax Pharmaceuticals's shares are less volatile than average (for this exchange).

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

What percentage of Syndax Pharmaceuticals is owned by insiders or institutions?
Currently 0.814% of Syndax Pharmaceuticals shares are held by insiders and 106.498% by institutions. How many people work for Syndax Pharmaceuticals?
Latest data suggests 184 work at Syndax Pharmaceuticals. When does the fiscal year end for Syndax Pharmaceuticals?
Syndax Pharmaceuticals's fiscal year ends in December. Where is Syndax Pharmaceuticals based?
Syndax Pharmaceuticals's address is: 35 Gatehouse Drive, Waltham, MA, United States, 02451 What is Syndax Pharmaceuticals's ISIN number?
Syndax Pharmaceuticals's international securities identification number is: US87164F1057 What is Syndax Pharmaceuticals's CUSIP number?
Syndax Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87164F105